Aligos Therapeutics, Inc. (ALGS) stock
ALGSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 9/3053% below fair value
$1.36−0.30 (-18.07%)
Close on Nov 17, 2026Market cap $16.99MP/E –Yield –
Aligos Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Aligos Therapeutics's price to sales ratio was 3.6× on Nov 11, 2026, against 22.5× a year earlier. Over the last 4 years it ranged from 3.6× to 346.6×, with a median of 10.0×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 3.6× | −18.3 |
| 2025 | Dec 31, 2025 | 21.9× | −14.2 |
| 2024 | Dec 31, 2024 | 36.0× | +30.8 |
| 2023 | Dec 29, 2023 | 5.2× | – |
See a number that looks wrong?